• Low flow conventional oxygen therapy is sufficient for most adult patients with SpO2<92%. Lower thresholds should be used in patients at risk of hypercapnic respiratory failure (SpO2 88–92% – see TSANZ Oxygen guidelines for acute oxygen use in adults).
• Its use in the treatment and management of patients with COVID-19 can be reviewed in the Australian guidelines for the clinical care of people with COVID-19.​
• HFNPO2 still remains an appropriate therapy for some people with respiratory failure from causes other than COVID-19.
• When starting HFNPO2, please document a detailed management plan for review and cessation of HFNPO2 – including end of life planning when appropriate.
• When HFNPO2 is the only appropriate therapy, administer in a negative pressure or single room using contact, droplet and airborne precautions. If this is not possible then efforts should be made to move the patient to a negative pressure or single room as soon as possible.
• Any room which has had an aerosol generating procedure in it requires airborne precautions for a minimum of 30 minutes after. The exact time depends on air changes per hour. See page 4 of  Infection Prevention and Control Novel Coronavirus 2019 (2019-nCoV) – Hospital setting from the Clinical Excellence Commission.
• Local sites should also consider local COVID-19 screening questions and processes in the context of local prevalence data when using HFNPO2.​

Document information